Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

Drug resistance to sorafenib is common in patients with hepatocellular carcinoma(HCC). We examined the effects of a combination of sorafenib and fluvastatin on HCC using in vitro and in vivo models. The dual treatment induced apoptosis and reduced cellular viability in HCC more effectively than eith...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yang, Luo, RongCheng, Zheng, Hang, Wang, Biao, Liu, YaHui, Liu, DingLi, Chen, JinZhang, Xu, WanFu, Li, AiMin, Zhu, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410302/
https://www.ncbi.nlm.nih.gov/pubmed/28423574
http://dx.doi.org/10.18632/oncotarget.15575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410302/
https://www.ncbi.nlm.nih.gov/pubmed/28423574
http://dx.doi.org/10.18632/oncotarget.15575

Ejemplares similares